Device type · CEW
Radioimmunoassay, Parathyroid Hormone
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
CEW
Clinical Chemistry
Device class
Class II
FDA decisions since 2015
7
510(k), De Novo and PMA
Adverse event reports
33
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Radioimmunoassay, Parathyroid Hormone
- Product code
- CEW
- Device class
- Class II
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.1545
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for CEW
Latest FDA decisions
K231927 · Decided Mar 22, 2024 · 266 days after receipt
Device type: Radioimmunoassay, Parathyroid Hormone (CEW) · Laboratory Medicine & Pathology
- Access Intact PTH510(k)
K232791 · Decided Mar 1, 2024 · 172 days after receipt
Device type: Radioimmunoassay, Parathyroid Hormone (CEW) · Laboratory Medicine & Pathology
K221197 · Decided Sep 5, 2023 · 498 days after receipt
Device type: Radioimmunoassay, Parathyroid Hormone (CEW) · Laboratory Medicine & Pathology
4 more FDA decisions with a free account
Reports received
33
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
31
94% of reports
Injury reports
2
6.1% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 1 | 0 | 0 | 0 |
| Jan 24 | 8 | 0 | 0 | 0 |
| Feb 24 | 2 | 0 | 0 | 0 |
| Mar 24 | 4 | 0 | 0 | 0 |
| Apr 24 | 7 | 0 | 0 | 0 |
| May 24 | 8 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 4 | 0 | 0 | 0 |
| Aug 24 | 10 | 0 | 0 | 0 |
| Sep 24 | 4 | 0 | 0 | 0 |
| Oct 24 | 16 | 0 | 0 | 0 |
| Nov 24 | 2 | 0 | 0 | 0 |
| Dec 24 | 2 | 0 | 0 | 0 |
| Jan 25 | 2 | 0 | 0 | 0 |
| Feb 25 | 2 | 1 | 0 | 0 |
| Mar 25 | 4 | 0 | 0 | 0 |
| Apr 25 | 3 | 0 | 0 | 0 |
| May 25 | 2 | 1 | 0 | 0 |
| Jun 25 | 1 | 0 | 0 | 0 |
| Jul 25 | 8 | 0 | 0 | 0 |
| Aug 25 | 1 | 0 | 0 | 0 |
| Sep 25 | 3 | 0 | 0 | 0 |
| Oct 25 | 7 | 0 | 0 | 0 |
| Nov 25 | 3 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 1 | 0 | 0 | 0 |
| Feb 26 | 2 | 0 | 0 | 0 |
| Mar 26 | 1 | 1 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 6 | 1 | 0 | 0 |
| Jun 26 | 4 | 0 | 0 | 0 |
| Jul 26 | 2 | 0 | 0 | 0 |
| Aug 26 | 4 | 0 | 0 | 0 |
| Sep 26 | 1 | 0 | 0 | 0 |
| Oct 26 | 7 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
1 more in this ranking with a free account
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- High Test Results15
- Low Test Results13
- Non Reproducible Results9
6 more in this ranking with a free account
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions31
- Insufficient Information2
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Siemens Healthcare Diagnostics, Inc.
Z-0366-2026 · Started Sep 22, 2025 · Posted by FDA Oct 27, 2025
Reason given: The potential for falsely depressed Intact PTH patient results at the low end of the assay range, less than or equal to 50 pg/mL (less than or equal to 5.3 pmol/L), when using specific lots identified by the firm on the IMMULITE 2000/IMMULITE 2000 XPi systems. The bias is observed in both serum and plasma samples.
Cause as FDA categorized it: Under Investigation by firm
Z-0803-2025 · Started Nov 26, 2024 · Posted by FDA Jan 3, 2025
Reason given: Beckman Coulter has identified that some Access PTH reagent packs from lot 339071 may be over- or under-filled in well 0. The dispensed material in well 0 could be above or below specification, risking sealing issues, contamination, instrument errors, delays, or inaccurate results with a negative bias and increase in...
Cause as FDA categorized it: Nonconforming Material/Component
Z-0673-2025 · Started Nov 8, 2024 · Posted by FDA Dec 11, 2024
Reason given: The reason for the recall is that EDTA and lithium heparin plasma samples that are stored in the DxI 9000 Access Immunoassay Analyzer sample wheel for a prolonged period before performing the intact PTH (parathyroid hormone) test may produce falsely decreased intact parathyroid hormone results. This could lead to a...
Cause as FDA categorized it: Process design
18 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.